|
|
 |
 |
|
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Affymax Appoints Hollings C. Renton to Board of Directors
Jun 10, 2009
|
6.1 KB
|
| |
PALO ALTO, Calif., Jun 10, 2009 (BUSINESS WIRE) -- Affymax, Inc., a clinical-stage pharmaceutical company, today announced
the appointment of Hollings C. Renton to the company's board of
directors.
Before retiring in 2008, Mr. Renton served as chairman of the board of
Onyx Pharmaceuticals, Inc. from 2000, where he also serv...
|
|
|
Affymax Announces Another Data Monitoring Committee Review of Phase 3 Hematide Program
Jun 3, 2009
|
8.6 KB
|
| |
PALO ALTO, Calif., Jun 03, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that the independent Data
Monitoring Committee (DMC), which provides oversight for the Phase 3
program for Hematide(TM), has completed another review and has informed the
company that the cumulative safety data generated thus far f...
|
|
|
Affymax(R) Reports Phase 2 Clinical Trial Data Supporting Hemoglobin Increases with Once-Per-Month Hematide(TM) Regardless of Patient Baseline Renal Function
May 26, 2009
|
8.8 KB
|
| |
PALO ALTO, Calif., May 26, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced data from a post hoc
analysis of 120 patients in a Phase 2 clinical trial of Hematide(TM) in
non-dialysis chronic kidney disease (CKD) patients. The data suggest
that there is no major impact of baseline renal function as measured ...
|
|
|
Affymax® Reports First Quarter 2009 Financial Results
May 7, 2009
|
11.0 KB
|
| |
PALO ALTO, Calif., May 07, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the
first quarter ended March 31, 2009. The net loss for the first quarter
of 2009 was $21.7 million compared to a net loss of $15.6 million for
the first quarter of 2008.
Affymax recognized revenue for the qu...
|
|
|
Affymax Reports Phase 2 Sub-Analysis of Hematide(TM) in Hemodialysis Patients
Mar 27, 2009
|
9.7 KB
|
| |
NASHVILLE, Tenn., Mar 27, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced data from a post hoc
sub-analysis of the Phase 2 clinical trial evaluation of Hematide in
chronic renal failure patients undergoing dialysis. These data suggest
that Hematide maintains stable hemoglobin levels in hemodialysis
...
|
|
|
Affymax to Present at Citi's 4th Annual Biotech Day
Mar 24, 2009
|
6.2 KB
|
| |
PALO ALTO, Calif., Mar 24, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq: AFFY) today announced that Paul B. Cleveland, the
company's chief financial officer and executive vice president of
corporate development, will present at Citi's 4th Annual
Biotech Day at 3:20 p.m. ET on April 1, 2009 in New York, NY.
A live webcast o...
|
|
|
Affymax(R) Reports Year End 2008 Financial Results
Mar 12, 2009
|
14.3 KB
|
| |
PALO ALTO, Calif., Mar 12, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today reported financial results for the
year ended December 31, 2008. The net loss for the year 2008 was $86.5
million compared to a net loss of $43.1 million for the year ended
December 31, 2007.
Affymax recognized revenue for the year ended De...
|
|
|
Affymax Announces Upcoming Webcasts and Conference Participation
Mar 2, 2009
|
6.2 KB
|
| |
PALO ALTO, Calif., Mar 02, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced the company's participation
at the following investor conferences during the month of March.
Barclays Global Healthcare Conference
Loews Miami Beach Hotel, Florida
March 10
...
|
|
|
Affymax Announces $42 Million Private Placement
Feb 17, 2009
|
5.5 KB
|
| |
PALO ALTO, Calif., Feb 17, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that it has obtained a
commitment from institutional investors to purchase approximately $42
million of its common stock in a private placement.
Under the terms of one of two types of purchase agreements, Affymax will
sell 2,844,7...
|
|
|
Affymax to Present at BIO CEO and Investor Conference
Feb 3, 2009
|
6.0 KB
|
| |
PALO ALTO, Calif., Feb 03, 2009 (BUSINESS WIRE) -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris,
president and chief executive officer, will present at the 11th
Annual BIO CEO & Investor Conference on Tuesday, February 10, 2009, at
2:15 p.m. ET at the Waldorf Astoria in New York City.
A live webcast of the...
|
|
|
The press releases may contain historical information and may no longer be accurate. Affymax disclaims any responsibility to update such information.
|
|
|
|
|
|
|
